Robert W. Baird Issues Positive Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its price objective boosted by Robert W. Baird from $61.00 to $63.00 in a report issued on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research firms have also recently commented on LIVN. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the company a “neutral” rating in a report on Wednesday, October 1st. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Barclays increased their target price on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

LivaNova Trading Up 1.8%

NASDAQ:LIVN traded up $0.88 during mid-day trading on Thursday, hitting $50.45. The company had a trading volume of 660,924 shares, compared to its average volume of 667,026. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The firm has a market cap of $2.75 billion, a P/E ratio of -12.97 and a beta of 1.00. The business’s fifty day moving average is $54.02 and its two-hundred day moving average is $48.25.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $357.80 million during the quarter, compared to analysts’ expectations of $342.32 million. During the same period in the prior year, the business posted $0.90 EPS. LivaNova’s revenue was up 12.5% on a year-over-year basis. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, research analysts expect that LivaNova will post 2.85 earnings per share for the current year.

Institutional Trading of LivaNova

Several large investors have recently modified their holdings of LIVN. Primecap Management Co. CA raised its stake in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock valued at $208,954,000 after purchasing an additional 32,942 shares in the last quarter. Vanguard Group Inc. grew its stake in LivaNova by 13.5% during the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock worth $104,755,000 after buying an additional 316,993 shares in the last quarter. AQR Capital Management LLC increased its holdings in LivaNova by 30.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock valued at $92,201,000 after buying an additional 478,525 shares during the period. Geode Capital Management LLC increased its holdings in LivaNova by 1.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,429,740 shares of the company’s stock valued at $64,374,000 after buying an additional 18,551 shares during the period. Finally, Artisan Partners Limited Partnership raised its position in shares of LivaNova by 112.9% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock valued at $56,167,000 after buying an additional 661,480 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.